Title
Emerging treatment options for complicated skin and skin structure infections: Oritavancin.
Document Type
Article
Date of Publication
2-11-2011
Publication Title
Clinical Medicine Insights: Therapeutics
First Page
25
Last Page
35
Abstract
Oritavancin is a semisynthetic lipoglycopeptide with in vitro activity against a variety of aerobic Gram-positive pathogens (including drug-resistant forms of staphylococci, streptococci, and enterococci) and select anaerobic organisms. Available published clinical efficacy and safety studies in humans to date focus primarily in the treatment of complicated skin and skin structure infections. While oritavancin doses in these studies varied, single daily doses of 200 mg (300 mg in patients > 100 kg) for 3–7 days have demonstrated efficacy similar to comparators (such as vancomycin followed by cephalexin). The most frequent adverse events reported to date include gastrointestinal complaints, insomnia, dizziness, itching, and rash. Further safety and efficacy data are needed to better define its potential place in therapy.
DOI
https://doi.org/10.4137/CMT.S2228
Recommended Citation
Pound, M. W.; Drew, R. H.; Wilson, D.; and Townsend, M. L., "Emerging treatment options for complicated skin and skin structure infections: Oritavancin." (2011). Pharmacy Practice. 647.
https://cufind.campbell.edu/pharmacypractice/647